Navigation Links
InVitria Reveals Technology to Optimize Hybridoma Production Performance
Date:4/22/2009

Article in Spring edition of Bioprocessing Journal reports InVitria's recombinant human serum albumin (Cellastim) and recombinant lactoferrin (Lacromin) cell culture supplements optimize cell growth and productivity in hybridoma cells.

Fort Collins, CO (PRWEB) April 22, 2009-- Recent studies using both classical media and the leading commercial serum-free hybridoma media formulations proved that InVitria's cell culture supplements optimized cell growth and productivity of hybridoma cells.1 Further, the studies revealed that Cellastim supports cell adaptation and survival in chemically-defined media.

Additional findings from the study showed that Cellastim improved the cell growth and productivity in long-term culture. In a 25-day period, cell doublings in Cellastim-supplemented media were twice that of media without Cellastim. Also, antibody production was 65% higher in the commercial media with Cellastim while cells supplemented with Cellastim grew to higher density than those in unsupplemented media.

"This research incorporated classical media as well as several leading commercial media available on the market," said Dr. Steve Pettit, the project's lead researcher. "We achieved optimal cell density and quicker doubling times as well as better cell productivity when Cellastim was added to these media. We also reported that Lacromin improves hybridoma cell culture performance."

Lacromin increased cell density in supplemented media nearly double compared to that of media without Lacromin supplementation. A significant increase in antibody production was recognized in all Lacromin-treated media, exceeding the level achieved with 5% fetal bovine serum (FBS).

"This research supports what customers have been reporting from their use of Cellastim and Lacromin for hybridoma cell culture," said InVitria President and CEO Scott Deeter. "Cellastim has been shown to not only optimize hybridoma performance, but also outperform other sources of native and recombinant albumin."

To obtain a copy of the above-mentioned article entitled, "Enhanced Growth and Productivity of a Hybridoma with Recombinant Human Albumin and Lactoferrin," please contact InVitria at info(at)InVitria(dot)com or 1-800-916-8311.

About InVitria
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture products and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research and diagnostics.

1Pettit S, Santos M, Tanner T, Huang N. Enhanced Growth and Productivity of a Hybridoma with Recombinant Human Albumin and Lactoferrin. BioProcessing Journal 2009; 8(1): 50-55.

###

Read the full story at http://www.prweb.com/releases/hybridomacells/hybridomaproduction/prweb2350604.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. InVitria Headlines Sponsorship of WilBio's Waterside Conference
2. InVitria Announces Launch of Recombinant Albumin for Diagnostics
3. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
4. InVitria's Cellastim Delivers Superior Results in CHO Cell Culture
5. InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego
6. InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting
7. InVitria to Present at WilBio's International Cell Engineering Meeting
8. Retirement Living TV Reveals: Sex Is The Real Fountain of Youth
9. New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies
10. New Research Reveals Need for Doctors to Know About Medical Tattoos
11. Study Reveals How Salmonella Hijacks Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) ... per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks ... (WCRI) . , According to the study, medical payments per claim in California decreased ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Hamilton County, is embarking on ... LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected senior ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a locally owned ... clients in the northern Alabama and Georgia regions, is embarking on a charity ... Works has built a network of support and education facilities to develop and ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Information products and services provider Elsevier ... Scopus , the world,s largest abstract and citation database of peer-reviewed ... journals from over 5,000 publishers. The new set of metrics will ... and when to adjust a journal,s editorial strategy. ... , , ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
(Date:12/8/2016)... , December 8, 2016 According to a ... Pulse, BP, Sleep, Fetal), Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), ... published by MarketsandMarkets, the global market, in terms of value, is projected ... at a CAGR of 18.0% during the forecast period. ... ...
Breaking Medicine Technology: